"In our study, we showed that fine needle aspiration (FNA) biopsy material can be a good source for next-generation sequencing (NGS) for patients with metastatic prostate cancer. Based on these ...
A novel blood based surveillance test using artificial intelligence and next-generation sequencing identified relapse a median of 41 days before clinical detection in patients with AML or MDS ...
The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high‑value healthcare solutions for transplant ...
Prospective real world data evaluation of clinical outcomes in metastatic hormone sensitive prostate cancer (MHSPC) patients treated as part of triplet therapy with darolutamide: UK multicenter ...
Precision medicine is key to developing more effective and less toxic treatments, representing the present and future of oncology research. This approach offers significant promise for incremental ...
Pattern of resistance on first-line EGFR-directed therapy in EGFR-positive metastatic non-small cell lung cancer. Utilizing TP53 mutation status and initial disease burden at presentation to ...
Children's Hospital Los Angeles (CHLA) and Thermo Fisher Scientific have agreed to develop a next-generation sequencing (NGS)-based panel designed specifically for pediatric cancer research. The assay ...
New xGen™ hybridization and wash offering is poised to revolutionize targeted next generation sequencing workflows Integrated DNA Technologies' new xGen™ Hybridization and Wash v3 Kit is poised to ...
Twist Bioscience's Q1 growth was modest, due in large part to an air pocket in demand caused by a large NGS customer. Read why TWST stock is a Buy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results